TAAR1 and hepatocellular carcinoma: Collectively, these results indicate that Tα1 might be used not only to prevent development of HCC from chronic hepatitis, but also to treat HCC once established, either the resectable and unresectable forms, most likely by keeping HBV replication and recurrences under control.